Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Cognitive peptides target neurotrophin signaling, synaptic plasticity, GABAergic tone, and neurogenesis pathways studied in the context of learning, memory, and neuroprotection. This guide covers four of the most-researched compounds — from clinically evaluated drugs in Russia to early-stage preclinical candidates — their mechanisms, what the evidence actually shows, and the regulatory picture. One of them is currently on the FDA Pharmacy Compounding Advisory Committee (PCAC) docket for the July 23–24, 2026 advisory meeting.
FDA PCAC Advisory Meeting — July 23–24, 2026
Semax is one of seven peptides on the FDA Pharmacy Compounding Advisory Committee (PCAC) docket for the July 23–24, 2026 meeting. The PCAC reviews nominations for the 503A Bulk Drug Substances List and makes recommendations — the FDA issues any final rule later. In April 2026, the FDA removed Semax and Selank (among 12 peptides) from Category 2 (the significant-safety-concern list), but this does not authorize compounding or place either compound on the Category 1 list. Track the regulatory status →
| Peptide | Primary Research Focus | Key Mechanism | Evidence Base | PCAC July 2026? |
|---|---|---|---|---|
| Semax | Neuroprotection, cognitive recovery, stroke | BDNF/NGF upregulation, TrkB activation | Russian RCTs (registered drug) | On docket |
| Selank | Anxiety reduction, antiasthenic (cognitive fatigue) | GABA-A positive allosteric modulation | Russian RCTs (registered drug) | — |
| Dihexa | Synaptogenesis, memory (Alzheimer's models) | HGF/c-Met facilitation, dendritic spine formation | Preclinical rodent only | — |
| P21 | Tau reduction, hippocampal neurogenesis (AD models) | CNTF-axis / BDNF upregulation, GSK-3β inhibition | Preclinical rodent only | — |
BDNF/NGF upregulator — most clinically evaluated cognitive peptide
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide derived from ACTH(4-10) with a C-terminal Pro-Gly-Pro extension that resists enzymatic degradation. It upregulates brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression in the hippocampus and cortex, and activates the BDNF/TrkB signaling pathway — which promotes neuronal survival, synaptic plasticity, and cognitive function. Semax also has melanocortin-receptor activity inherited from the ACTH(4-10) core, but lacks the steroidogenic C-terminal region, so it does not activate the HPA axis or drive cortisol output. Additional reported effects include inhibition of enkephalin-degrading enzymes and modulation of dopaminergic and serotonergic tone.
Semax is the best-documented cognitive peptide in this guide. It has been registered as a drug in Russia since 1994 — as a 0.1% intranasal preparation for cognitive and asthenic conditions, and as a 1% preparation for acute ischemic stroke and optic nerve disease. Russian clinical trials by Gusev, Skvortsova, and colleagues documented improved neurological recovery scores when Semax was initiated within the first hours of ischemic stroke. Its neurotrophic mechanism (BDNF upregulation) aligns well with established pathways in cognitive neuroscience. The limitation: essentially the entire clinical evidence base is Russian-language literature, and no Western RCTs or regulatory trials have been conducted. Western researchers have largely not replicated or extended the Russian findings in independent studies.
GABA-A modulator — anxiolytic with antiasthenic cognitive effects
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro; also known as TP-7) is a synthetic heptapeptide analog of the endogenous immunomodulatory tetrapeptide tuftsin, with a Pro-Gly-Pro C-terminus added for metabolic stability. It acts as a positive allosteric modulator at GABA-A receptors, modulates serotonergic and monoaminergic neurotransmission, and inhibits enkephalin-degrading enzymes — extending endogenous opioid peptide signaling. The tuftsin-derived backbone also confers immunomodulatory activity. Selank increases BDNF and modulates expression of genes involved in GABAergic neurotransmission, producing a calming, antianxiety effect without the sedation or dependence risk profile of classical benzodiazepines in Russian clinical data.
Selank is registered in Russia as a 0.15% intranasal solution for generalized anxiety disorder and asthenic conditions. The pivotal Russian comparison by Zozulia et al. (2008) reported anxiolytic efficacy comparable to medazepam — a classical benzodiazepine — with additional antiasthenic (anti-fatigue, pro-cognitive) effects and a more favorable tolerability profile. The 'antiasthenic' effect reported in Russian clinical literature corresponds to improved attention, reduced mental fatigue, and normalized motivation — cognitive benefits often observed alongside anxiety reduction. Limitations: the evidence base is entirely Russian-language institutional studies; no US or EU regulatory trials have been conducted; the Russian clinical methodology does not always meet Western RCT standards for blinding and reporting.
HGF/c-Met synaptogen — extraordinary preclinical, no human data
Dihexa (PNB-0408) is a small-molecule hexapeptide-like analog of angiotensin IV, designed to bind hepatocyte growth factor (HGF) and facilitate HGF/c-Met receptor dimerization at concentrations well below the threshold where endogenous HGF alone produces activation. HGF/c-Met signaling in the brain drives dendritic spine formation and synaptogenesis in hippocampal circuits. Unlike most cognitive compounds that act on established neurotransmitter receptors, Dihexa directly promotes structural synaptic plasticity — the formation of new dendritic connections between neurons. It was designed with oral bioavailability and blood-brain barrier penetration in mind. The often-cited claim that it is 'roughly ten million times more potent than BDNF' refers to EC50 comparisons in a specific in vitro dendritic spine assay, not clinical or behavioral potency.
McCoy et al. (J Pharmacol Exp Ther, 2013, PMID 23055539) showed that oral Dihexa reversed scopolamine-induced memory deficits and improved Morris water maze performance in aged rats at low doses. Additional preclinical work demonstrated rescue of cognitive impairment in APP/PS1 Alzheimer's mouse models. However, the evidence picture is complicated: (1) A 2014 mechanistic paper from the same research group on HGF/c-Met-dependent synaptogenesis was retracted in 2025 and should not be cited; (2) Dihexa was licensed and developed into the related analog fosgonimeton (ATH-1017) by Athira Pharma — whose Phase 2/3 LIFT-AD trial in Alzheimer's disease failed its primary endpoint in 2024 and was discontinued; (3) No human clinical trial of Dihexa itself has been published. The c-Met target is also a proto-oncogene pathway, raising theoretical concerns about proliferative safety that have not been evaluated in humans.
CNTF-derived neurogenic peptide — anti-tau, hippocampal neurogenesis
P21 (also P021; Ac-DGGL[A]G-NH2) is a small peptidergic compound derived from an active region (residues ~148-151) of human ciliary neurotrophic factor (CNTF), developed by Khalid Iqbal's laboratory at the New York State Institute for Basic Research in Developmental Disabilities. Preclinical data suggest P21 competitively antagonizes leukemia inhibitory factor (LIF) signaling at the gp130/LIFR complex, de-inhibiting hippocampal neurogenesis. Downstream, it increases BDNF expression, activates TrkB → PI3K/Akt signaling, and inhibits GSK-3β — reducing tau hyperphosphorylation, a key pathological feature of Alzheimer's disease. The compound's adamantyl modification targets oral bioavailability and blood-brain barrier penetration.
Kazim et al. (Neurobiology of Disease, 2014, PMID 25046994) showed that chronic oral P21 rescued memory and learning in 3xTg-AD mice (a widely used Alzheimer's model), increased dentate gyrus neurogenesis, and reduced tau hyperphosphorylation. Additional preclinical work from the Iqbal group demonstrated dendritic and synaptic rescue in aging and AD mouse models. Chronic rodent dosing studies up to ~18 months reported no overt toxicity, tumors, or pain behaviors — but rodent safety does not establish human safety. No Phase 1/2/3 human trial of P21 has been published. No human safety, pharmacokinetic, or carcinogenicity data exist. P21 is not a drug candidate with an active clinical development program and is purely a preclinical research compound.
Cognitive peptides — particularly Semax and Selank — are relatively low-volume compounds in the grey-market research peptide supply chain. Lower volume means less competitive pressure on quality, and a higher rate of substitution or underdosing in some vendor batches. Structural similarity between Semax and Selank (both heptapeptides with Pro-Gly-Pro termini) means mass spectrometry confirmation of the molecular weight is especially important — not just HPLC purity alone. Disclosed Labs maintains an independent COA corpus for Semax, Selank, and other cognitive peptides, drawn from Janoshik, ILS, Vanguard, and Freedom Diagnostics.
Semax Regulatory Tracker
Live status of Semax in the 2026 FDA PCAC review
Best Peptides for Longevity
Epitalon, MOTS-c, DSIP, and five other anti-aging compounds
FDA Category 1 Guide
What the 2026 reclassification means for compounding
Are Peptides Safe?
Side effects, risks, and what the research shows
Semax vs Selank
Side-by-side mechanism and evidence comparison
The most extensively researched cognitive peptides in the scientific literature are Semax and Selank, both developed at the Institute of Molecular Genetics (Russian Academy of Sciences) and registered as drugs in Russia. Semax has the strongest evidence base — it is registered for ischemic stroke and cognitive/asthenic conditions, backed by peer-reviewed Russian clinical trials. Selank has published RCT data for generalized anxiety disorder with additional cognitive (antiasthenic) effects. Dihexa and P21 are earlier-stage research compounds with impressive preclinical data but no published human clinical trials. All four are research compounds in the United States — not FDA-approved treatments.
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide derived from ACTH(4-10) with a Pro-Gly-Pro C-terminal extension that stabilizes it against enzymatic degradation. Developed at the Russian Academy of Sciences, it has been registered in Russia since 1994 as intranasal drops for cognitive/asthenic indications and as a 1% preparation for acute ischemic stroke and optic nerve disease. Mechanistically, Semax upregulates BDNF and NGF expression in the hippocampus and cortex and activates the BDNF/TrkB signaling pathway. Russian clinical trials by Gusev, Skvortsova, and colleagues reported improved neurological recovery when Semax was started early in acute ischemic stroke. The evidence base is primarily Russian-language literature — no Western regulatory approvals or pivotal Western trials have been conducted.
Semax and Selank are both synthetic heptapeptides developed at the same Russian Institute and share the Pro-Gly-Pro C-terminal stability extension, but they target different primary pathways. Semax emphasizes neurotrophic effects — BDNF/NGF upregulation and TrkB activation — and is primarily studied in contexts requiring cognitive recovery or neuroprotection after acute insult (stroke, optic nerve disease). Selank acts primarily as a positive allosteric modulator at GABA-A receptors, with modulation of serotonergic and monoaminergic neurotransmission, producing predominantly anxiolytic and antiasthenic effects. The pivotal Russian Zozulia et al. (2008) comparison found Selank anxiolytic efficacy comparable to medazepam (a benzodiazepine) with added cognitive/antiasthenic benefits. In practice, Semax and Selank are often researched together because their mechanisms are complementary — one primarily neurotrophic, one primarily anxiolytic/GABAergic.
Dihexa (PNB-0408) is distinct from most cognitive peptides because it works through the hepatocyte growth factor (HGF) / c-Met receptor pathway rather than classical neurotransmitter or neurotrophin systems. Developed at Washington State University by the Harding/Wright group, Dihexa promotes dendritic spine formation and hippocampal synaptogenesis by facilitating HGF binding to c-Met at concentrations well below what endogenous HGF achieves alone. Preclinical rodent studies (McCoy et al., J Pharmacol Exp Ther, 2013) showed reversal of scopolamine-induced memory deficits and improved Morris water maze performance. However, it is important to note: (1) No published human clinical trial of Dihexa itself has been conducted; (2) A related compound, fosgonimeton (ATH-1017), which targets the same HGF/c-Met pathway, failed its Phase 2/3 LIFT-AD trial in Alzheimer's disease in 2024; (3) One 2014 mechanistic paper from the Dihexa research group was retracted in 2025. The HGF/c-Met pathway is also a proto-oncogene signaling pathway, raising theoretical cancer-related safety considerations that have not been evaluated in humans.
P21 (also P021) is a small peptidergic compound derived from an active region of human ciliary neurotrophic factor (CNTF), developed by Khalid Iqbal's laboratory at the New York State Institute for Basic Research in Developmental Disabilities. It is designed to mimic CNTF's neurogenic and neurotrophic effects by modulating the gp130/LIFR signaling complex, increasing BDNF expression, and downstream inhibiting GSK-3β to reduce tau hyperphosphorylation — a key pathological hallmark of Alzheimer's disease. Kazim et al. (Neurobiology of Disease, 2014) demonstrated that chronic oral P21 rescued cognition, boosted hippocampal neurogenesis, and reduced tau hyperphosphorylation in the 3xTg-AD mouse model. P21 has never been tested in a human clinical trial. No human safety, pharmacokinetic, or carcinogenicity data exist. It is purely a preclinical research compound.
Yes. Semax is one of seven peptides on the FDA Pharmacy Compounding Advisory Committee (PCAC) docket for the July 23–24, 2026 advisory meeting. The PCAC reviews nominations for the 503A Bulk Drug Substances List and makes recommendations — the FDA issues any final rule later. In April 2026, the FDA removed 12 peptides (including Semax) from Category 2 (the significant-safety-concern list), but this does not authorize compounding and does not place Semax on the Category 1 (503A) compoundable list. Semax's compounding eligibility depends on the outcome of the PCAC review and any subsequent FDA rulemaking.
No. None of the cognitive peptides covered in this guide — Semax, Selank, Dihexa, or P21 — are FDA-approved drugs in the United States. Semax and Selank are registered drugs in Russia. Dihexa and P21 have only been tested in animal models and are purely experimental. In the United States, these compounds are research chemicals sold for laboratory and scientific research purposes. Semax is on the FDA PCAC advisory docket for July 2026, which may affect its future compounding eligibility, but no approval or authorization currently exists. Always consult a licensed healthcare provider and regulatory attorney for guidance on use or access.
A reliable Certificate of Analysis (COA) for a cognitive peptide should include: (1) HPLC purity — look for ≥98% for research-grade compounds; (2) Mass spectrometry (MS) confirmation that the molecular weight matches the expected sequence; (3) An identifiable third-party laboratory name — Janoshik, ILS, Vanguard, Freedom Diagnostics, and Kovera are common research labs; (4) A lot number matching the specific product batch. Cognitive peptides are particularly susceptible to degradation and substitution due to their structural similarity and low market volume — independent COA verification matters more, not less, for these compounds. Disclosed Labs maintains a public COA corpus with verified lot numbers across vendors.
Disclosed Labs